Literature DB >> 2177401

Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.

G Barnett1, J Segura, R de la Torre, M Carbó.   

Abstract

Quinolone is reported to interact with caffeine, often resulting in an increase both in the plasma half-life and AUC, a decrease in total plasma clearance, and little change in the absorption rate constant and maximum plasma level. These complex changes in the pharmacokinetics of caffeine were analyzed experimentally and from published reports in order to determine the nature of the interaction, which is thought to be due to inhibition of caffeine metabolism by quinolones. A simple pharmacokinetic model for the caffeine-quinolone interaction was developed, which provides a unified method for evaluation and comparison of the effect of quinolones on the disposition of caffeine. The model is applicable to other methylxanthines, such as theophylline. The relative potency of the interactions of quinolones with caffeine in humans has been established as enoxacin (100), pipemidic acid (29), ciprofloxacin (11), norfloxacin (9) and ofloxacin (0).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177401     DOI: 10.1007/BF02657060

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.

Authors:  G Arcieri; E Griffith; G Gruenwaldt; A Heyd; B O'Brien; P Screen; N Becker; R August
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

2.  A clinically significant interaction between ciprofloxacin and theophylline.

Authors:  A H Thomson; G D Thomson; M Hepburn; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles.

Authors:  P N Shaw; J B Houston
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

4.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

Review 5.  The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.

Authors:  D E Nix; J J Schentag
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

6.  Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males.

Authors:  A H van der Willigen; J C van der Hoek; J H Wagenvoort; H J van Vliet; B van Klingeren; W O Schalla; J S Knapp; T van Joost; M F Michel; E Stolz
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 7.  Inhibition of drug metabolism by quinolone antibiotics.

Authors:  D J Edwards; S K Bowles; C K Svensson; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

8.  Effect of quinolones on caffeine disposition.

Authors:  M Carbó; J Segura; R De la Torre; J M Badenas; J Camí
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

9.  4-quinolones inhibit biotransformation of caffeine.

Authors:  S Harder; A H Staib; C Beer; A Papenburg; W Stille; P M Shah
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.

Authors:  G Ho; M G Tierney; R E Dales
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

View more
  7 in total

1.  In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system.

Authors:  H Kita; H Matsuo; H Takanaga; J Kawakami; K Yamamoto; T Iga; M Naito; T Tsuruo; A Asanuma; K Yanagisawa; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 3.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

4.  Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.

Authors:  K Takagi; K Yamaki; M Nadai; T Kuzuya; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.

Authors:  G Mahr; F Sörgel; G R Granneman; M Kinzig; P Muth; K Patterson; U Fuhr; P Nickel; U Stephan
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 6.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

Review 7.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.